Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus DIPHENHYDRAMINE.
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus DIPHENHYDRAMINE.
CHILDREN'S ALLEGRA HIVES vs Diphenhydramine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
Inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and GI tract; also anticholinergic by blocking muscarinic receptors and sedative via central H1 receptor antagonism.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
25-50 mg orally or intramuscularly every 4-6 hours; maximum 300 mg/day. Intravenous administration: 10-50 mg slow IV push (max 25 mg/min).
None Documented
None Documented
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Clinical Note
moderateDiphenhydramine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Diphenhydramine."
Clinical Note
moderateDiphenhydramine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate."
Clinical Note
moderateDiphenhydramine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diphenhydramine."
Clinical Note
moderateTerminal elimination half-life 4-8 hours in adults; prolonged in hepatic impairment (up to 20 hours) and elderly.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Primarily renal (90-95% as metabolites, <5% unchanged). Minor biliary/fecal elimination (<5%).
Category C
Category C
Antihistamine
Antihistamine
Diphenhydramine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diphenhydramine."